Perfect Medical Health Management Limited (PFSMF) Fair Value & Analysis
Healthcare · US · Market cap $302M
Fair value as of: Jun 24, 2026
Analysis
Perfect Medical Health Management Limited (PFSMF) currently trades at $0.2401, while our model-based Fair Value estimate is $0.3800 — implying the stock looks roughly 58.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Perfect Medical Health Management Limited, an investment holding company, engages in the provision of medical, aesthetic medical, and beauty and wellness services in Hong Kong, the People's Republic of China, Macau, Australia, and Singapore. The company offers pain management and hair growth treatments; preventive care and fertility care services; and sleep therapy treatment services under the Goku Spa brand name. It also provides advertising, charitable, and management services, as well as holds trademarks and rents equipment. The company was formerly known as Perfect Shape Medical Limited and changed its name to Perfect Medical Health Management Limited in June 2021. Perfect Medical Health Management Limited was founded in 2003 and is headquartered in Mong Kok, Hong Kong.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Perfect Medical Health Management Limited (PFSMF) undervalued?
What is the fair value of PFSMF?
What is the quality score of PFSMF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.